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Asthma is one of the classic diseases 
recognized by Hippocrates over 2000 years 
ago, yet it remains a serious global health 
problem because it is still not yet well 
understood. Asthma prevalence is reported to 
be on the increase worldwide especially among 
children (Kemp, 2003). Fortunately, recent 
advances in science have improved our 
understanding of asthma and the ability to 
manage it effectively (GINA, 2004) although 
deaths from asthma far from disappearing, 
have become more frequent in some countries 
(Jackson et al, 1982). 
Previously, most information on the 
pathology of asthma was obtained from 
postmortem tissue. Macroscopically, in 
patients that died of asthma the lungs are over 
– inflated, with both large and small airways 
filled with plugs comprised of a mixture of 
mucus, serum proteins, inflammatory cells, 
and cell debris. Microscopically, the findings 
are usually of extensive infiltration of the 
airway lumen and wall with eosinophils and 
lymphocytes, vasodilatation, evidence of micro 
vascular leakage and epithelial disruption 
(Dunnil, 1960; Krait et al, 1996). 
More recently, studies of living subjects 
with asthma have involved endobronchial 
biopsies of patients with mild disease, which 
have generally reflected the findings at 
autopsy. However studies in patients with 
more severe asthma suggest that in addition to 
eosinophils and lymphocytes, neutrophils are 
also present and may play a role in more 
severe disease (Wenzel et al, 1997).  
Currently, the application of 
immunological and molecular biological 
techniques to asthma has greatly improved 
understanding of the disease. This has placed T 
– lymphocytes as pivotal cells in orchestrating 
the inflammatory response through the release 
of multifunctional cytokines (Robinson et al, 
1992). In addition to potent mediators that 
contract airway smooth muscle, increase micro 
vascular leakage, activate different neurons 
and stimulate mucus secreting cells, a number 
of factors are released that have the capacity to 
produce structural changes in the airways or 
attract inflammatory cells to cause injury to the 
bronchial tissue. Chemokines have also been 
shown to play a crucial role in the recruitment 
of inflammatory cells to the airways (Bousquet 
et al, 2000). 
 
Airway Remodeling 
Asthma is currently recognized as a 
chronic inflammatory disorder of the airways 
that leads to tissue injury and subsequent 
structural changes collectively called airway 
remodeling (Homer and Elias, 2005). The 
inflammatory process in asthma is dominated 
by so – called Th2 inflammation, characterized 
by T cells that make interleukin (IL) – 4, - 5, 
and – 13 along with the classically described 
eosinophil - , mast cell - , basophil - , and 
macrophage – rich  inflammation (Cohn et al, 
2004). This is in contrast to Th1 T cells, which 
make interferon - γ, lymphotoxin, and IL – 2. 
Th1 and Th2 cells differentiate into polarized 
populations from a common precursor on the 
basis of signals from the local 
microenvironment. After they have developed, 
Th1 and Th2 cells are commonly thought to 
inhibit the development of the other cell type. 
In addition, there are regulatory cells that also 
appear to regulate the appearance of each cell 
type. Th1 cells play a dominant role in 
controlling intracellular pathogens like 
tuberculosis, whereas Th2 cells play a 
dominant role in controlling extracellular 
pathogens like parasites and mites, and 
allergens like dusts and pollens (Alakija et al, 
1990). However, the absence of either 
population leads to enhanced 
immunopathology, even in conditions 
classically thought to depend on the other cell 
type. 
It is thought that inflammation alone may 
lead to some features of asthma, including 
reversible bronchospasm. However, as with 
many chronic inflammatory disorders, 
asthmatic airway inflammation is also believed 
to cause tissue injury and subsequent structural 
changes. These changes are referred to 
collectively as airway remodeling and include 




1) an increase in overall wall thickness, 2) an 
increase in airway fibrosis and 3) smooth 
muscle mass, 4) abnormalities in composition 
of the extracellular matrix, and 5) an increase 
in vascularity (Homer and Elias, 2000). These 
changes have attracted interest due to the 
increased realization that these changes may 
account for aspects of asthmatic physiology 
that are poorly addressed with current anti – 
inflammatory strategies (Busse at al, 2004). 
 
Analysis and Studies on Airway Remodeling 
In fatal asthma, pathological analysis 
has shown that most elements of the airway 
wall (smooth muscle, non – smooth muscle 
connective tissue, mucus glands) are increased 
(Carroll et al, 1993; Huber and Koessler, 1922; 
James et al, 1989; Kuwano et al, 1993). The 
changes (except for the increase in mucus 
glands) are found in airways of all sizes (Saetta 
et al, 1991). The pathological changes in 
airways of patients with nonfatal asthma are 
much less pronounced, with changes seen 
predominantly in small airways (2 – 4 mm in 
diameter) (Carroll et al, 1997; Kuwano et al, 
1993). Airway wall thickness as measured 
radiologically also correlates with disease 
severity and length of time with disease, with 
small airways again being the predominant 
abnormality in milder disease (Awadh et al, 
1998; Boulet et al, 1995; Goldin et al, 1998; 
Harmanci et al, 2002; Kasahara et al, 2002; 
Little et al, 2002; Okazawa et al, 1996 and 
Paganin et al, 1996). 
An increase in airway smooth muscle 
mass is one of the best – known features of 
asthmatic remodeling (Huber and Koessler, 
1922). Like total wall thickness, smooth 
muscle thickness correlates with fatal or 
nonfatal asthma (Carroll et al, 1993; James et 
al, 1989 and Kuwano et al, 1993). The degree 
to which hyperplasia compared with 
hypertrophy contributes to this response 
continues to be controversial, but both 
probably contribute in different patient 
populations (Benayoun et al, 2003; Ebina et al, 
1993, and Woodruff  et al, 2004). The degree 
to which this increased smooth muscle is 
abnormal is also controversial (Benayoun et al, 
2003 and Woodruff et al, 2004). 
An increase in fibrosis just below the large 
airway epithelium occurs as a prominent 
feature in asthma. This layer has been 
extensively studied due to its accessibility on 
endobronchial biopsy. The normal layer of 
collagen under the airway is ∼ 5 µm thick, 
which increases to 7 – 23 µm in patients with 
asthma. Initially described as basement 
membrane thickening, it is now apparent that 
the true basement membrane (the lamina rara 
and densa as seen on electron microscopy, 
which contain laminin and collagen IV) is not 
grossly altered (Roche et al, 1989). There is, 
rather, thickening of the area just below the 
true  basement membrane, the lamina 
reticularis, with deposition of interstitial 
collagens I, III, and V. Studies have reported 
correlations of subepithelial fibrosis as 
measured in larger cartilaginous airways with 
overall wall thickness in the same airways but 
not in small airways elsewhere in the same 
lung (James et al, 2002 and Kasahara et al, 
2002). There are inconsistent results with 
respect to enhanced collagen deposition in the 
submucosa (area between the layer of dense 
subepithelial fibrosis and smooth muscle) 
(Benayoun et al, 2003; Chu et al, 1998 and 
Wilson and Li, 1997). Abnormalities have also 
been noted in noncollagenous matrix, 
including elastin, proteoglycans, and cartilage 
(Lazaar and Panettieri, 2003). 
The significance of this specific feature of 
asthmatic airway remodeling is unclear. 
Although measurements of airway 
distensibility correlate well with subepithelial 
fibrosis (Ward et al, 2001), other functional 
measurements (clinical illness scores, 
measures of pulmonary function and airway 
hyperresponsiveness) show variable 
correlations (Benayoun et al, 2003; Boulet et 
al, 1997; Chetta et al, 1997; Cho et al, 1996 
and Hoshina et al, 1998). Other groups have 
identified severe asthmatics with no increase in 
subepithelial fibrosis (Chakir et al, 2003; Chu 
et al, 1998 and Wenzel et al, 1999). 
Subepithelial fibrosis is actually a very early 
marker for the asthmatic phenotype in children 
and does not correlate with length of time with 
the disease nor necessarily with the severity of 
inflammation (Boulet et al, 2000; Chu et al, 
1998; Cokugras et al, 2001; Laitinen et al, 
1996 and Payne et al, 2003). It has therefore 
been suggested that subepithelial fibrosis 
represents disordered epithelial – 
mesenchymal signaling rather than a direct 
response to inflammatory injury (Holgate et al, 
2004). A tracheal explant model has shown 
that cigarette smoke can induce remodeling in 
the absence of inflammation, indicating that 
other pathways to fibrosis need to be 
considered (Wang et al, 2003 and Iyawe et al, 
2005).         
Myofibroblasts are specialized cells with 
features of both fibroblasts and myocytes. 
They have the synthetic machinery of 
fibroblasts used for synthesis of extracellular 
matrix but also have at least some components 
of the contractile apparatus of myocytes. They 
are well known to be increased in tissues 
undergoing repair, such as in wounds or in 




pulmonary interstitial fibrosis. In human 
asthma, the submucosa shows an increase in 
myofibroblasts that correlates with the 
thickness of the lamina reticularis but not with 
severity of disease (Benayoun et al, 2003; 
Brewster et al, 1990 and Hoshino et al, 1998). 
Since myofibroblasts are well known sources 
of interstitial collagens, it is plausible to 
suggest that the myofibroblasts are the source 
of the subepithelial fibrosis. The origin and 
fate of these cells is somewhat obscure. Cells 
with this phenotype appear very quickly after 
antigen challenge, possibly implying a 
quiescent precursor cell that acquires 
myofibroblastic markers without necessarily 
dividing (Gizycki et al, 1997). Other data 
suggest that these cells may arise from 
circulating precursors (Schmidt et al, 2003). 
Increased vascularity is a common feature 
of chronic inflammation. In addition, increased 
vascular congestion, leading to wall 
thickening, has been suggested as the basis of 
exercise – induced asthma, the airway 
hyperresponsiveness seen in congestive heart 
failure and in normal subjects after a rapid 
infusion of intravenous fluids (Cabanes et al, 
1989 and Rolla et al, 1986). More severe 
asthmatics have a greater number of vessels 
than milder asthmatics (Salvato, 2001 and 
Vrugt et al, 2000). Increased vascularity is 
noted in both newly diagnosed patients and in 
patients with long – standing asthma. There is 
a correlation of vascularity with airway 
hyperresponsiveness and change in lung 
function after bronchodilator treatment 
(Hoshino et al, 2001 and Orsida et al, 1999). 
The vessels that are increased appear to be 
capillaries and venules and are concentrated 
just under the airway epithelium (Orsida et al, 
2001 and Salvato, 2001). Abnormalities of  
various types of vessels in the airway mucosa 
have also been described. (Salvato, 2001). 
Paradoxically, but consistent with results 
measuring other aspects of airway remodeling, 
there is no correlation of degree of abnormality 
with length of time with disease. As in animal 
models, in patients, vascularity is denser in 
intercartilagenous areas than over cartilage 
(McDonald, 2001). 
 
Mechanisms of Airway Remodeling 
A large number of mediators have been 
described in airways of asthmatics that could 
theoretically be relevant to airway remodeling. 
In many cases, the presence of these mediators 
correlates with the severity of airway 
remodeling or some clinical feature. However, 
it is difficult to know the significance of these 
findings in the absence of a specific inhibitor 
of that mediator. So far, only one specific 
mediator, IL–5, has been targeted in humans. 
IL-5 was well established as potentially 
relevant to asthma on account of its powerful 
influence on eosinophil development and 
priming. Treatment of asthmatics with a 
humanized anti – IL-5 antibody confirmed this 
suspicion, because it caused a marked 
reduction in circulating and airway lumen 
eosinophils and a lesser reduction in airway 
tissue eosinophils. Furthermore, treatment with 
this antibody was able to reduce matrix 
proteins present beneath the epithelial 
basement such as tenascin C and lumican 
(Flood-Page et al, 2003). Whether this effect 
of anti – IL-5 on matrix turnover is eosinophil 
dependent is not known because airway 
fibroblasts and epithelial cells also possess IL-
5 receptors. Unfortunately, despite these 
impressive biological effects, the antibody 
failed to produce any clinically significant 
effect on asthmatic physiology. 
IL-13 has been shown to be critically 
important in acute models of allergic 
inflammation (Wills-Karp et al, 1998). It was 
originally discovered as an IL-4 like molecule 
with which it shares some receptor subunits. It 
has since become clear that IL-13 is more 
important in the effector phase and that IL-4 is 
more important in the initiation phase of Th2 
inflammation. With the use of both 
conventional and inducible transgenic 
modeling, IL-13 was shown to be a potent 
inducer of an eosinophils -, macrophage -, and 
lymphocyte – rich inflammatory response, 
airway fibrosis, mucus metaplasia, and airway 
hyperresponsiveness (Zhu et al, 1999). IL-13 
mediates many of its effects through a signal 
transducer and activator of transcription 
(STAT)-6 signaling pathway, and human 
asthmatics have elevated levels of STAT-6 in 
airway epithelium (Mullings et al, 2000). 
Collagen deposition in tissues is 
controlled by the balance of the collagen – 
degrading matrix metalloproteinases (MMPs) 
and their inhibitors, the tissue inhibitors of 
metalloproteinases (TIMPs). In addition to 
their role in matrix remodeling, it has also 
become apparent that MMPs have important 
roles in inflammation, angiogenesis, and cell – 
cell signaling (Kelly and Jarjour, 2003). In 
asthma, the potentially most important 
members of this family are MMP-9 and TIMP-
1. MMP-9 is produced in an exaggerated 
fashion by asthmatic alveolar macrophages and 
is found in exaggerated quantities in sputum, 
bronchoalveolar lavage (BAL) fluid, and 
biopsies from patients with asthma. The ratio 
of MMP-9 and TIMP-1 in asthmatics is lower 
than in control subjects and correlates with the 




degree of airway obstruction (Kelly and 
Jarjour, 2003).    
Other Th2 cytokines, such as IL-9 and IL-
10, appear to function at least partly via 
inducing IL-13 (Lee et al, 2002 and Whittaker 
et al, 2002). IL-10 has been considered in 
some cases a Th2 cytokine but has also been 
implicated in immunoregulation. Mice that 
overexpress IL-10 in the airway show a 
reduction in aspects of innate immunity, 
including endotoxin – induced tumor necrosis 
factor production and neutrophil accumulation. 
However, IL-10 also causes mucus metaplasia, 
B cell - and T cell – rich inflammation, and 
airway fibrosis and augments the levels of 
mRNA encoding Gob-5, mucins, and IL-13. 
These responses are mediated by multiple 
mechanisms, with mucus metaplasia being 
dependent on an IL-13-IL-4Rα-STAT-6 
pathway, whereas the inflammation and 
fibrosis were independent of that pathway (Lee 
et al, 2002). 
The most heavily studied mediator of 
tissue fibrosis is transforming growth factor 
(TGF)-β1. TGF-β1 is made by many cells 
within the lungs, such as epithelial cells, 
macrophages, eosinophils, lymphocytes, and 
fibroblasts. TGF-β1 can induce fibroblast and 
smooth muscle proliferation and enhances 
matrix production. TGF-β1 mRNA appears to 
be increased in moderate and severe asthmatics 
compared with normal subjects, and the 
expression of this cytokine is directly related to 
the degree of subepithelial fibrosis (Minshall et 
al, 2000 and Ohno et al, 1996). As determined 
by using in situ hybridization, eosinophils and 
fibroblasts are the principal cells synthesizing 
TGF-β1 in the airway, whereas alveolar 
macrophages release more TGF-β1 from 
asthmatics than from controls (Hoshino et al, 
1998; Vignola et al, 1997 and Vignola et al, 
1996). Expression of downstream signaling 
molecules from TGF-β also shows an increase 
in asthma and a correlation with subepithelial 
fibrosis (Nakao et al, 2000 and Sagara et al, 
2002). Macrophages were the major site of 
TGFβ-1 production as assessed by 
immunohistochemistry and in situ 
hybridization. IL-13-induced fibrosis was 
significantly ameliorated by treatment with the 
TGF-β antagonist soluble TGFβR-Fc (Lee et 
al, 2001).. It is possible, therefore, that the 
main significance of MMP-9 overexpression in 
human asthma may be to activate TGF-β1 (Lee 
et al, 2001). 
A large number of factors are known that 
control airway smooth muscle cell 
proliferation in vitro (Panettieri, 2003). 
However, little is certain about their role in 
vivo. IL-11, a member of the IL-6 – type 
cytokine family, shares a common receptor – 
signaling subunit with IL-6 and has been 
shown to induce airway hyperresponsiveness 
in mice when administered intratracheally 
(Einarsson et al, 1996 ). It is produced by a 
variety of lung stromal cells, including 
epithelial cells, smooth muscle cells, and 
fibroblasts, in response to a variety of stimuli, 
including asthma – related viruses, histamine, 
and eosinophils major basic protein (Einarsson 
et al, 1996 and Elias et al, 1994). 
Overexpression of IL-11 in the lungs caused an 
increase in peribronchial fibrosis and an 
increase in true airway smooth muscle mass 
and myofibroblasts (Tang et al, 1996). There is 
an increase in baseline airway resistance and 
marked airway hyperresponsiveness. The 
studies with the IL-11 mice led to analysis of 
human airways that showed that IL-11 is 
overexpressed in chronic human asthma but 
only in the most severely remodeled airways 
(Minshall et al, 1999). 
Increased vascularity may be due to any 
number of proangiogenic factors, especially 
vascular endothelial growth factor (VEGF). 
VEGF was originally described as vascular 
permeability factor on the basis of its ability to 
generate tissue edema. It has subsequently 
been appreciated to be a multi – functional 
angiogenic regulator that stimulates epithelial 
cell proliferation, blood vessel formation, and 
endothelial cell survival (Clauss, 2000 and 
Gerber et al, 1998). VEGF levels are increased 
in asthmatics, and levels correlate directly with 
disease activity and inversely with airway 
caliber and airway responsiveness (Asai et al, 
2002; Hoshino et al, 2001 and Lee and Lee, 
2001). VEGF has been postulated to contribute 
to asthmatic tissue edema via its vascular 
permeability factor effect (Anthony et al, 2002 
and Thurston et al, 2000). IL-13 is known to 
cause an increase in VEGF production (Corne 
et al, 2000). In mice that over - express VEGF, 
there is a dramatic endothelial sprouting under 
the airway epithelium (Lee et al, 2004), potent 
induction of angiogenesis and edema in the 
airway and lung. There is evidence for 
remodeling, with an increase in smooth muscle 
mass around airways. Later there is an increase 
in collagen around airways. TGF-β1 was also 
increased at this latter time point. These airway 
and lung changes were accompanied by an 
increase in airway hyperresponsiveness. 
VEGF also caused a marked increase in 
inflammation, with an increase in mononuclear 
cells, T and B cells, and eosinophils. There 
was an increase in the number and activation 
state of dendritic cells that correlated with 
ability to prime the mice via the airways, a 
feature not found in wild – type mice. 




As expected from the IL-13 – over expressing 
mice, after allergen challenge, VEGF was 
found to be markedly increased in BAL fluids. 
In the lung, VEGF is localized to airway 
epithelial cells, mononuclear cells, and T cells. 
In vitro, polarized Th2 cells are much more 
potent producers of VEGF than Th1 cells. 
When a VEGF receptor antagonist was used in 
vivo, there was a dramatic decrease in BAL 
and tissue inflammation as well as airway 
hyper responsiveness. There was also a 
decrease in IL-13 and IL-4 production (Lee et 
al, 2004). 
These results suggest a positive feed – 
forward circuit in which allergen challenge 
increases VEGF while VEGF also increases 
allergic inflammation, dendritic cell activation 
and airway remodeling. It is thought that viral 
infection early in life can predispose one to the 
development of asthma (Schwarze and 
Gelfand, 2002 and Sigurs et al, 2000). Because 
viral infection can also lead to increased VEGF 
(Einarsson et al, 1996), these results suggest a 
mechanism whereby this may occur. Finally, 
given the ability of VEGF to promote both 
inflammation and airway remodeling, this data 
supports a possible role for VEGF antagonists 
in therapy of asthma, especially in severe 




Physiological Significance of Airway 
Remodeling 
Airway remodeling has been invoked to 
explain various aspects of asthma severity, 
including airway hyper responsiveness and 
fixed airway obstruction (Busse et al, 2004). 
The cross – sectional studies comparing fatal 
and nonfatal asthma certainly support the 
general concept of a relationship between 
airway remodeling and asthma severity. 
Although experimental studies of allergic 
models show that airway hyper responsiveness 
can be induced without airway remodeling 
(Hoshino et al, 1998) and individual cytokines 
are known that can increase airway smooth 
muscle responsiveness both in vitro and in 
vivo (Amrani and Panettieri, 1998 and 
Einarsson et al, 1996) a murine model of 
airway remodeling suggests that airway 
dysfunction persists after resolution of 
inflammation, implicating the airway 
remodeling itself in airway dysfunction (Leigh 
et al, 2002). Extensive mathematical modeling 
also suggests effects of airway remodeling on 
airway function similar to those seen clinically 
(Okazawa et al, 1996). 
Fixed airway obstruction associated with 
progressive loss of lung function has now been 
demonstrated in several cohort studies of both 
adults and children (Covar et al, 2004; Lang et 
al, 1998; Peat et al, 1987 and Ulrik et al, 
1992). Although the pathological basis for this 
phenomenon is not completely known, studies 
have shown a remarkable correlation of asthma 
severity with measures of smooth muscle area, 
smooth muscle hypertrophy, and density of 
fibroblasts in the airway wall (Benayoun et al, 
2003). Interestingly, another group had not 
only not seen this effect, they also saw a 
correlation of subepithelial fibrosis with 
disease severity, which was specifically not 
seen by the first group (Cho et al, 1996). It is 
possible that this represents disease 
heterogeneity. 
A number of papers have addressed the 
issue of reversibility of airway remodeling. 
Early studies showed no effect of steroids on 
subepithelial fibrosis (Jeffrey et al, 1992; 
Lundgren et al, 1988 and Roche et al, 1989). 
More recent randomized studies have shown a 
significant reduction in subepithelial fibrosis 
after short – term or long – term therapy or 
after withdrawal from exposure to antigen 
(Chetta et al, 1997; Hoshino et al, 1998; Saetta 
et al, 1995 and Ward et al, 2002). It has been 
suggested that prior treatment with steroids, 
delayed treatment, or low doses and short 
courses of steroids prevented an effect from 
being noted in the earlier studies. Steroids also 
decrease the number of (myo)fibroblasts in the 
submucosa and reduce airway vascularity 
(Chetta et al, 2003; Hoshino et al, 1998; 
Hoshino et al, 2001 and Orsida et al, 1999). 
The decrease in vessel number correlates with 
the decrease in airway hyper responsiveness, 
reduction in inflammation, and change in 
subepithelial collagen (Chetta et al, 2003 and 
Hoshino et al, 2001). One study suggests that 
addition of a β2 – agonist to inhaled steroids 
may reduce vascularity further (Orsida et al, 
2001). These pathological studies have been 
used to support the suggestion from clinical 
trials that early treatment with inhaled steroids 
is required to prevent irreversible loss of lung 
function, at least in adults (Haahtela et al, 
1994; Overbeek et al, 1996 and Selroos et al, 
1995).  
Recent advances in the treatment and 
management of asthma have shown that 
leukotriene (LT) receptor antagonists or LT 
modifiers are very beneficial as a second 
generation therapy with steroid – sparing 
properties and negligible side effects (Moqbel, 
1999, and Mission et al, 1999). 
A few studies have addressed the issue of 
response of putative remodeling mediators to 
therapy. TGF-β appears resistant to steroid 
therapy, whether there is a reduction in 




measures of airway remodeling or not (Chakir 
et al, 2003 and Hoshino et al, 1998). However, 
since remodeling presumably requires more 
than one mediator and because alternative 
pathways are likely, it is hard to interpret this 
kind of data. 
There remain many areas of uncertainty in this 
field. Despite the suggestion that airway 
remodeling explains the lack of response to 
therapy of some patients, no study has 
specifically shown that those patients who 
either fail to respond to therapy or progress 
despite therapy do in fact show airway 
remodeling (or excess expression of some 
mediator of remodeling) that fails to respond 
or progresses despite a reduction in 
inflammation. No prospective study has 
examined the effects of therapy on smooth 
muscle. Finally, one explanation for the 
disparate results discussed here is that of 
clinical heterogeneity, i.e., different 
subpopulations of patients have different 
aspects of airway remodeling related to their 
particular physiology. If this hypothesis was 
true, it would ultimately be necessary to 
characterize the pathological basis of each 
patient’s physiology before determining which 
therapy would be most beneficial in reversing 
or preventing airway remodeling in that 
individual patient. This field remains open for 
research, especially in relation to treatment.  
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